1 week ago
It was reported on February 18, that Jeffrey V Poulton, EVP at Alnylam Pharmaceuticals (NASDAQ:ALNY) executed a significant insider sell, according to an SEC filing.
What Happened: Poulton's recent move involves selling 2,242 shares of Alnylam Pharmaceuticals. This information is documented in a Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday. The total value is $695,201.
Alnylam Pharmaceuticals's shares are actively trading at $330.02, experiencing a down of 0.83% during Wednesday's morning session.
Discovering Alnylam Pharmaceuticals: A Closer Look
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway in cells that enables sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Financial Insights: Alnylam Pharmaceuticals
Positive Revenue Trend: Examining Alnylam Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 84.95% as of 31 December, 2025, showcasing a substantial increase in ...
